IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Timolol in the Treatment of Asian Populations with Chronic Angle-Closure Glaucoma
Li, Shi-Ming1; Chen, Ru2; Li, Yuan3; Yang, Zhi-Rong2; Deng, Qiu-Ju4; Zhong, Zheng3; Ong, Moh-Lim5; Zhan, Si-Yan2
刊名PLOS ONE
2014-05-09
DOI10.1371/journal.pone.0096852
9期:5
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
资助者Pfizer China, Beijing ; Pfizer China, Beijing
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]TERM CLINICAL COURSE ; CILIARY-BODY FACE ; OCULAR HYPERTENSION ; PREVALENCE ; DISTRICT ; CHINESE ; EFFICACY ; 6-MONTH
英文摘要

Background: To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG).

Methods: Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included absolute and relative reduction of intraocular pressure (IOP) at mean, peak and trough from baseline, ocular adverse effects and systemic adverse events.

Results: Seven randomized controlled trials with 685 patients were included. In comparison with timolol, latanoprost reduced absolute IOP in CACG patients by more than 2.3 mmHg (95% CI, 1.8 similar to 2.9, P<0.01), 2.4 mmHg (95% CI, 1.9 similar to 2.9, P<0.01) and 2.5 mmHg (95% CI, 1.6 similar to 3.3, P<0.01) at mean, peak and trough, respectively. As for relative IOP, there is 9.0% (95% CI, 6.6 similar to 11.4, P<0.01), 9.7% (95% CI, 7.6 similar to 11.8, P<0.01), and 10.8% (95% CI, 7.4 similar to 14.3, P<0.01) greater reduction among latanoprost users than among timolol users. The differences were statistically significant at all time points (1, 2, 4, 8, 12, and 24 weeks). More ocular adverse effects (OR = 1.49, 95% CI, 1.05 similar to 2.10, P = 0.02) and less systemic adverse events (OR = 0.46, 95% CI, 0.25 similar to 0.84, P = 0.01) were observed in latanoprost group in comparison with timolol group.

Conclusion: Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients.

语种英语
资助者Pfizer China, Beijing ; Pfizer China, Beijing
WOS记录号WOS:000336838000071
Citation statistics
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66307
Collection北京大学公共卫生学院
作者单位1.Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China
2.Peking Univ, Dept Epidemiol & Hlth Stat, Sch Publ Hlth, Beijing 100871, Peoples R China
3.Pfizer China, Beijing, Peoples R China
4.Pfizer Global Pharmaceut, New York, NY USA
5.Peking Univ, Dept Genet, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
Recommended Citation
GB/T 7714
Li, Shi-Ming,Chen, Ru,Li, Yuan,et al. Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Timolol in the Treatment of Asian Populations with Chronic Angle-Closure Glaucoma[J]. PLOS ONE,2014,9(5).
APA Li, Shi-Ming.,Chen, Ru.,Li, Yuan.,Yang, Zhi-Rong.,Deng, Qiu-Ju.,...&Zhan, Si-Yan.(2014).Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Timolol in the Treatment of Asian Populations with Chronic Angle-Closure Glaucoma.PLOS ONE,9(5).
MLA Li, Shi-Ming,et al."Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Timolol in the Treatment of Asian Populations with Chronic Angle-Closure Glaucoma".PLOS ONE 9.5(2014).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Li, Shi-Ming]'s Articles
[Chen, Ru]'s Articles
[Li, Yuan]'s Articles
百度学术
百度学术Similar articles in
[Li, Shi-Ming]'s Articles
[Chen, Ru]'s Articles
[Li, Yuan]'s Articles
必应学术
必应学术Similar articles in
[Li, Shi-Ming]'s Articles
[Chen, Ru]'s Articles
[Li, Yuan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.